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ABSTRACT 
Advances in optical coherence tomography have enabled a better appreciation of the role of pathologic choroidal 
changes in a variety of retinal disease. A “pachychoroid” (pachy-[prefix]: thick) is defined as an abnormal and permanent 
increase in choroidal thickness often showing dilated choroidal vessels and other structural alterations of the normal 
choroidal architecture. Central serous chorioretinopathy is just one of several pachychoroid-related macular disorders. 
This review summarizes the current state of knowledge of the pachycoroid spectrum and the hallmark features seen 
with multimodal imaging analysis of these entities 
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INTRODUCTION 
Rapid progress in retinal imaging has provided new 
insights into a variety of chorioretinal disorders. 
Advances in optical coherence tomography (OCT) are 
perfect examples of this trend. Following the first 
descriptions of retinal OCT imaging (1–3), the subsequent 
evolution led to improvements in resolution to better 
visualize the retinal structure (4–6). More recently, 
further advances in choroidal imaging occurred.  Coming 
on of enhanced depth imaging (EDI) (7) and swept source 
OCT technologies (8) have enabled more precise analysis 
of the choroid both qualitatively and quantitatively. 
Three different layers of choroidal tissue may be 
differentiated between Bruch’s membrane and the 
sclera-choroidal junction: choriocapillaris is the 
innermost portion; Sattler’s layer, composed of small 
oval vascular patterns, and Haller’s layer consisting of 
large outer oval vascular patterns (9). This qualitative 
analysis is rough, and in the absence of pathologic 
changes all three layers may be found in a high-
penetration OCT (both EDI and SS). On the other hand, 
the quantitative analysis of choroidal thickness is more 
variable. Choroidal thickness decreases with increasing 
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age and axial length (10–12). Gender is not associated 
with differences in choroidal thickness (13). Transiently 
increased choroidal thickness was associated with acute 
stages of several posterior uveitis such as Vogt-Koyanagi-
Harada disease (14), multifocal choroiditis (15) and the 
multiple evanescent white dot syndrome (16). 
The term pachychoroid (pachy-[prefix]: thick) was 
proposed as a term indicating an abnormal and 
permanent increase in choroidal thickness, This entity 
often occurs in eyes with central serous 
chorioretinopathy (CSC) or CSC-like features (17–19). 
Eyes with a pachychoroid change often manifest 
dilatation of the large choroidal vessels compressing the 
overlying choriocapillaris and Sattler’s layer (19). The aim 
of the present review is to define the morphological 
characteristics of the pachychoroid occurring in CSC and 
to analyze the new spectrum of diseases sharing similar 
choroidal findings (Fig. 1). 
 
Central Serous Chorioretinopathy 
Central serous chorioretinopathy is characterized by the 
presence of subretinal fluid often associated with serous 
pigment epithelial detachment (PED). Abnormalities of 
the choroidal circulation are believed to play an 
important role in the pathophysiology of this entity. 
Choroidal congestion and hyperpermeability have been 
frequently described in this disease (20–22). The 
correlate of such findings on OCT imaging is increased 
choroidal thickness (pachychoroid), particularly involving 
Haller’s layer, as the unifying feature of all types of CSC 
(23,24). The chronic presence of fluid may manifest as 
focal areas of speckled hyperautofluorescence and 
eventually to gravitational zones corresponding to serous 
retinal detachments (Fig. 1) (24,25). 
 
Pachychoroid Pigment Epitheliopathy 
Pachychoroid pigment epitheliopathy (PPE) is a newly 
described entity with characteristic features on 
multimodal imaging of the macula (18). This entity is 
distinguished from typical CSC as the patients 
manifesting with retinal pigment epithelium (RPE) but 
had no documented subretinal fluid. Pachychoroid 
pigment epitheliopathy may represent a formae frustae 
of CSC, similar in nature to the findings often seen in the 
fellow eye of patients presenting with unilateral acute 
CSC. 
• Fundus examination often shows an orange-reddish 
appearance and absence of normal tessellation what 
indicates an underlying pachychoroid. Present changes in 
pigment include: RPE alterations that might be mistaken 
for age-related maculopathy (ARM), a pattern dystrophy 
of the RPE or non-neovascular age-related macular 
degeneration (AMD). These changes may include sub-
RPE deposits similar in appearance to typical drusen. 
• OCT imaging shows numerous, scattered small 
elevations of the RPE representing RPE hyperplasia and 
sub-RPE drusen-like deposits (Fig. 2). Occasionally, small 
serous PEDs are present. The defining feature of PPE on 
OCT is a thick choroid usually located directly beneath 
the clinically apparent RPE change. Large choroidal 
vessels in the Haller’s layer often approximate Bruch’s 
membrane without superseding Sattler’s layer (Fig. 2). 
• Indocyanine green angiography (ICGA) reveals 
choroidal hyperpermability as mid-phase 
hyperfluorescence that co-existent with the areas of RPE 
disturbances. 
• Fundus autofluorescence shows areas of granular 
hypoatuofluorescence and mixed stippled hyper- and 
hypoautofluorescence. Signs of antecedent subretinal 
fluid, such as gravitational tracts, zonal areas of 
hyperautofluorescence or focal areas of speckled 
hyperautofluorescence are never seen in PPE. 
 
Pachychoroid Neovasculopathy 
Pachychoroid neovasculopathy (PNV) is considered a late 
complication of PPE and chronic CSC in patients who 
presumably carry a genetic risk for choroidal 
neovascularization (19). The unique imaging findings 
include features similar to those described for PPE and 
CSC, but eyes with PNV also show evidence of sub-RPE 
neovascular tissue -type 1 neovascularization- (26). 
Pachychoroid neovasculopathy may be discovered as an 
incidental finding in patients with a history of CSC, with 
or without associated subretinal fluid collections. 
Patients lacking a history of CSC may present with 
symptoms of an exudative maculopathy related to this 
slow-growing form of choroidal neovascularization. The 
current hypothesis suggests that in susceptible 
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individuals, long-term effects on the RPE, Bruch’s 
membrane and choriocapillaris induced by a 
pachychoroid may lead to the subsequent development 
of type 1 neovascularization (27,28). 
• Optical coherence tomography imaging in PNV shows a 
broad shallow elevation of the RPE representing 
neovascular proliferation within Bruch’s membrane (26). 
This form of type 1 neovascularization is typically found 
overlying an area of localized choroidal thickening with 
dilated choroidal vessels (Fig. 3). 
 
Figure 1. Forty year-old man with typical CSC 
Autofluorescence image (top right) shows mottling 
hyperautofluorescence. Fluorescein angiography identifies the 
juxtafoveal leaking point (middle row). OCT showing subretinal fluid 
with photoreceptor outer segment elongation (bottom row). 
 
 
 
 
 
 
 
 
Figure 2. Morphologic changes identified in the OCT images of cases 
with PPE 
Small elevation of the retinal pigment epithealium (top row), drusen-
like deposits underneath the retinal pigment epithelium (bottom 
row). All cases show large choroidal vessels within choroidal Haller’s 
layer approaching Bruch’s membrane with the absence of an 
intervening Sattler’s layer. 
 
 
 
Figure 3. Fifty-three-year-old man with typical changes of 
pachychoroid neovasculopathy 
Color photographed evidenced orange-reddish appearance and 
absence of standard tessellation (top left) Fundus autofluorescence 
image showed focal changes of granular hypoatuofluorescence and 
mixed stippled hyper and hypoautofluorescence (top right). 
Indocyanine green angiography revealed a significant choroidal 
hyperpermeability (bottom left). OCT evidenced a broad shallow 
elevation of the retinal pigment epithelium representing a type 1 
neovascular proliferation with associated flat subretinal fluid (bottom 
right). 
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• Indocyanine green angiography often shows both mid-
phase patchy areas of choroidal hyperpermability and a 
discrete plaque of late hyperfluorescence corresponding 
to type 1 neovascular tissue. 
Eventually, polypoidal choroidal vasculopathy (PCV) may 
develop, within or at the margins of the slow-growing 
type 1 neovascular tissue. The polyps may produce an 
exudative maculopathy that includes both lipid 
deposition and hemorrhagic complications. The polyps 
are easily identified with ICGA as early focal areas of 
intense hyperfluorescence that may show either late 
leakage or “wash-out” appearance depending on their 
degree of activity. 
 
CONCLUSION 
Enhanced depth imaging and SS OCT have enabled a 
better appreciation of the role of pathologic choroidal 
changes in CSC. Furthermore, they have helped defining 
an expanded spectrum of pachychoroid-related macular 
disorders. Recognition of these entities is important as 
they may mimic other diagnoses that have different 
natural courses and treatments. For example, the clinical 
appearance of PPE may simulate ARM, AMD, or pattern 
dystrophies. Similarly, without choroidal imaging, PNV 
may easily be mistaken for neovascular AMD. 
The occurrence of PCV in eyes with PNV adds further 
evidence that PCV is a natural evolution of type 1 
neovascular proliferation rather than a disease sui 
generis. 
In our experience, eyes with exudation due to PNV, 
irrespective of the presence of  PCV, are more resistant 
to anti-vascular endothelial growth factor (anti-VEGF) 
agents than eyes with choroidal neovascularization 
(CNV). This is presumably due to the typical AMD and 
myopic macular degeneration. Thus, the recognition of 
an underlying pachychoroid in neovascularized maculo- 
pathies may have important implications regarding their 
management. Since the photodynamic therapy is 
intended to reduce choroidal thickness and 
hyperpermeability, it surely warrants further exploration 
(29,30). 
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